Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis

被引:13
作者
Bauer, Alicja
Habior, Andrzej
机构
[1] Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw
[2] Department of Gastroenterology, Hepatology and Clinical Oncology Centre of Postgraduate Medical Education, Warsaw
[3] Clinic of Polish Gastroenterology Foundation, Warsaw
关键词
primary biliary cholangitis; liver fibrosis; autoantibodies; metalloproteinases; MMP-3; CHRONIC HEPATITIS-C; LIVER FIBROSIS; ANTINUCLEAR ANTIBODIES; EXPRESSION; PROGRESSION; MMPS; ASSOCIATION; ENDOSTATIN; PROGNOSIS; DIAGNOSIS;
D O I
10.3389/fimmu.2022.885229
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and AimsMetalloproteinases (MMPs) are involved in many distinct processes in the liver. Matrix metalloproteinase-3 (MMP-3) plays an important role in connective tissue remodeling, degradation of collagen (types II, III, IV, IX, and X), proteoglycans, fibronectin, laminin, and elastin. In addition, MMP-3 can also activate other MMPs such as MMP-1, MMP-7, and MMP-9. Primary biliary cholangitis (PBC) is a cholestatic, autoimmune liver disease, characterized by the progressive destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and liver failure. Fibrosis is the result of an imbalance between production and degradation of the extracellular matrix surrounding hepatocytes. Our aim in the present study was to determine whether the measurement of serum MMP-3 is clinically useful for assessing ongoing liver fibrosis in patients with PBC. MethodsThe MMP-3 concentration was determined in 182 PBC patients and 80 non-PBC controls using a commercially available ELISA kit. ResultsHigher concentrations of MMP-3 were found in 61% of PBC patients. PBC subjects had greater MMP-3 levels than controls: 68.9 +/- 62.6 vs 21.3 +/- 7.4 ng/mL, p < 0.001 for healthy subjects; 68.9 +/- 62.6 vs 22.7 +/- 7.6 ng/mL, p = 0.022 for autoimmune hepatitis controls; and 68.9 +/- 62.6 vs 37.2 +/- 17.4 ng/mL, p = 0.002 for primary sclerosing cholangitis controls. The serum MMP-3 concentration was significantly elevated in patients with higher bilirubin concentration (107.6 +/- 85.8 vs 61.6 +/- 46.1 ng/mL, p < 0.001) and was correlated with the level of antimitochondrial antibodies specific for PBC. The concentration of MMP-3 in sera of PBC patients was also found to correlate with the state of liver fibrosis (OR = 4.3; p < 0.01). ConclusionsOur study demonstrated significantly higher MMP-3 levels in PBC patients than in healthy and pathological controls. Increased MMP-3 concentrations were positively correlated with various clinical and immunological parameters, and advanced liver fibrosis. The level of MMP-3 was associated with hepatic dysfunction and could play a role in the pathophysiology of hepatic fibrosis in PBC.
引用
收藏
页数:9
相关论文
共 50 条
[1]   Matrix metalloproteinase-3 serum levels in schizophrenic patients [J].
Ordak, Michal ;
Libman-Sokolowska, Malgorzata ;
Nasierowski, Tadeusz ;
Badyra, Bogna ;
Kaczmarek, Leszek ;
Muszynska, Elzbieta ;
Bujalska-Zadrozny, Magdalena .
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2023, 27 (01) :1-7
[2]   Prognostic significance of serum tyrosine concentration in patients with primary biliary cholangitis under ursodeoxycholic acid therapy [J].
Amano, Nozomi ;
Ikeda, Yuji ;
Hayashida, Sho ;
Takahashi, Sho ;
Sato, Sho ;
Murata, Ayato ;
Tsuzura, Hironori ;
Sato, Shunsuke ;
Shimada, Yuji ;
Iijima, Katsuyori ;
Wada, Ryo ;
Nagahara, Akihito ;
Genda, Takuya .
HEPATOLOGY RESEARCH, 2020, 50 (02) :214-223
[3]   High serum matrix metalloproteinase-3 and liver stiffness in postoperative biliary atresia [J].
Honsawek, Sittisak ;
Praianantathavorn, Kesmanee ;
Chongsrisawat, Voranush ;
Vejchapipat, Paisarn ;
Theamboonlers, Apiradee ;
Poovorawan, Yong .
PEDIATRIC SURGERY INTERNATIONAL, 2011, 27 (07) :681-687
[4]   Effect of matrix metalloproteinase-3 functional SNP on serum matrix metalloproteinase-3 level and outcome measures in Japanese RA patients [J].
Tsukahara, S. ;
Shinozaki, M. ;
Ikari, K. ;
Mochizuki, T. ;
Inoue, E. ;
Tomatsu, T. ;
Hara, M. ;
Yamanaka, H. ;
Kamatani, N. ;
Momohara, S. .
RHEUMATOLOGY, 2008, 47 (01) :41-44
[5]   Serum Level of Matrix Metalloproteinase-3 in Patients with Oral Lichen Planus [J].
Farzin, M. ;
Mardani, M. ;
Ghabanchi, J. ;
Fattahi, M. J. ;
Rezaee, M. ;
Heydari, S. T. ;
Tadbir, A. Andisheh .
IRANIAN RED CRESCENT MEDICAL JOURNAL, 2012, 14 (01) :10-13
[6]   Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients [J].
Cozzolino, Mario ;
Biondi, Maria Luisa ;
Galassi, Andrea ;
Turri, Olivia ;
Brancaccio, Diego ;
Gallieni, Maurizio .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (07) :2207-2212
[7]   Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients [J].
Zeng, Xiaoli ;
Li, Siting ;
Tang, Shiyi ;
Li, Xi ;
Zhang, Guoyuan ;
Li, Mengtao ;
Zeng, Xiaofeng ;
Hu, Chaojun .
FRONTIERS IN IMMUNOLOGY, 2021, 12
[8]   Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy [J].
Ohtsuka, Tomoaki ;
Nishimura, Kazuhisa ;
Kurata, Akira ;
Ogimoto, Akiyoshi ;
Okayama, Hideki ;
Higaki, Jitsuo .
JOURNAL OF CARDIAC FAILURE, 2007, 13 (09) :752-758
[9]   Evaluation of serum matrix metalloproteinase-3 as a biomarker for diagnosis of epilepsy [J].
Wang, Rui ;
Zeng, Guang Qun ;
Liu, Xu ;
Tong, Rui Zhan ;
Zhou, Dong ;
Hong, Zhen .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 367 :291-297
[10]   A low baseline serum myostatin concentration is associated with poor clinical outcome in patients with primary biliary cholangitis [J].
Hayashi, Manabu ;
Abe, Kazumichi ;
Sugaya, Tatsuro ;
Takahata, Yosuke ;
Fujita, Masashi ;
Takahashi, Atsushi ;
Ohira, Hiromasa .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (10) :2069-2076